Analyst firms · Raymond James · VRTX
Raymond James VRTX price target and rating history
Vertex Pharmaceuticals Incorporated (VRTX) · Health Care
Raymond James rates Vertex Pharmaceuticals Incorporated (VRTX) Mkt Perform, as of its latest action on Sep 3, 2025. It has published 3 rating actions on VRTX since July 2021, including 0 upgrades and 0 downgrades. Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50.
- Current rating
- Mkt Perform
- Price target
- Not stated
- Median target, all firms
- $577.50
- Actions on VRTX
- 3
Every Raymond James rating on VRTX
- Sep 3, 2025
- Oct 10, 2024
- Jul 1, 2021
How other firms rate VRTX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Outperform | $594 | Sep 21, 2026 |
| Morgan Stanley | Overweight | $665 | Sep 2, 2026 |
| Truist Securities | Buy | $542 | May 27, 2026 |
| Maxim Group | Buy | $575 | Mar 18, 2026 |
| Jefferies | Buy | $580 | Mar 10, 2026 |
| Oppenheimer | Outperform | $600 | Mar 10, 2026 |
| Barclays | Overweight | $606 | Jan 28, 2026 |
| RBC Capital Markets | Outperform | $546 | Jan 22, 2026 |
| Bernstein | Outperform | Jan 12, 2026 | |
| UBS | Buy | $535 | Jan 7, 2026 |
| Wolfe Research | Outperform | $548 | Jan 6, 2026 |
Questions about Raymond James and VRTX
- What is Raymond James's rating on VRTX?
- Raymond James rates VRTX Mkt Perform, a neutral rating, as of Sep 3, 2025.
- When did Raymond James last change its view on VRTX?
- On Sep 3, 2025, Raymond James starts coverage at Mkt Perform.
- How does Raymond James's VRTX target compare with other analysts?
- Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50.
More VRTX rating histories
- Leerink Partners7
- Morgan Stanley6
- Maxim Group3
- Jefferies3
- Oppenheimer3
- RBC Capital Markets7
- Bernstein3
- Wolfe Research5
- Wells Fargo3
- Canaccord Genuity4
- Piper Sandler3
All Raymond James ratingsVRTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.